<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4650">
  <stage>Registered</stage>
  <submitdate>30/07/2013</submitdate>
  <approvaldate>30/07/2013</approvaldate>
  <nctid>NCT01913613</nctid>
  <trial_identification>
    <studytitle>REDUCE LAP-HF TRIAL</studytitle>
    <scientifictitle>REDUCE LAP-HF TRIAL: A Study to Evaluate the DC Devices, Inc. IASD System II to REDUCE Elevated Left Atrial Pressure in Patients With Heart Failure</scientifictitle>
    <utrn />
    <trialacronym>REDUCE LAP-HF</trialacronym>
    <secondaryid>2013-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - IASD

Experimental: Treatment - Treatment with the IASD device


Treatment: devices: IASD
IASD device implantation

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>MACCE - subjects who experience major adverse cardiac and cerebrovascular events (MACCE) defined as death, stroke, MI; or subjects who experience a systemic embolic event (excluding pulmonary thromboembolism)</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          1. Chronic symptomatic Heart Failure (HF) documented by one or more of the following:

               1. New York Heart Association (NYHA) Class II/III/ambulatory class IV symptoms
                  (Paroxysmal nocturnal dyspnea, Orthopnea, Dyspnea on mild or moderate exertion)
                  at screening visit; or signs (Any rales post cough, Chest x-ray demonstrating
                  pulmonary congestion,) within past 12 months;

               2. One hospital admission for which HF was a major component of the hospitalization
                  within the 12 months prior to study entry (transient heart failure in the context
                  of myocardial infarction does not qualify);

               3. On-going management with recommended heart failure medications and comorbidities
                  for several months according to the guidelines (2012 ESC Guidelines for diagnosis
                  and Treatment of Acute and Chronic Heart Failure).

          2. Age = 40 years old

          3. Left ventricular ejection fraction (obtained by echocardiography) = 40%

          4. Elevated left ventricular filling pressures with a gradient compared to CVP documented
             by :

               1. PCWP or LVEDP at rest = 15 mmHg, and greater than CVP, OR

               2. PCWP during supine bike exercise = 25mm Hg, and CVP &lt; 20 mm Hg

        Key</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>3. Severe heart failure defined as:

          1. ACC/AHA/ESC Stage D heart failure, Non-ambulatory NYHA Class IV HF;

          2. Fick Cardiac Index &lt; 2.0 L/min/m2

          3. Requiring inotropic infusion (continuous or intermittent) within the past 6 months

          4. Patient is on the cardiac transplant waiting list 4. Inability to perform 6 Minute
             Walk Test 5. Known significant coronary artery disease (stenosis &gt;70%) 6. History of
             stroke, transient ischemic attack (TIA), deep vein thrombosis (DVT), or pulmonary
             emboli within the past 6 months 7. Known severe carotid artery stenosis (&gt; 70%) 8.
             Presence of significant valve disease defined by echocardiography as: a) Mitral valve
             regurgitation defined as grade &gt;2+ MR b) Tricuspid valve regurgitation defined as
             grade = 2+ TR; c) Aortic valve disease defined as = 2+ AR or moderate AS</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/07/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>The Prince Charles Hospital - Brisbane</hospital>
    <hospital>David Kaye - Melbourne</hospital>
    <hospital>St. Vincent Hospital - Sydney</hospital>
    <postcode> - Brisbane</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Sydney</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Aalst</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dusseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gottingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nieuwegein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Harefield</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Corvia Medical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of this clinical study is to evaluate the safety and performance of the IASD
      System II in the treatment of heart failure patients with elevated left atrial pressure, who
      remain symptomatic despite appropriate medical management.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01913613</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jan Komtebedde, DVM</name>
      <address>Corvia Medical</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>